Dual-chemokine-armed oncolytic Senecavirus A co-recruits cDC1 and CXCR3+ T cells to convert 'cold' melanoma and drive durable regression - PubMed
18 hours ago
- #oncolytic virotherapy
- #chemokine engineering
- #melanoma immunotherapy
- Engineered recombinant Senecavirus A (SVA) to co-express chemokines CXCL11 and vXCL1 for synergistic immune cell recruitment.
- Deletion of signal peptides improved genetic stability and intratumoral payload retention without affecting viral fitness.
- CXCL11 monotherapy enhanced tumor control, prolonged survival, and suggested protection against tumor rechallenge in mouse models.
- Combination of CXCL11 and vXCL1 increased dendritic cell activation, CD8+ T-cell infiltration, and M1 macrophage polarization.
- The dual-chemokine approach led to deeper and more durable tumor regression in 'cold' melanoma models.